Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Assets Average (2018 - 2025)

Sutro Biopharma's Assets Average history spans 8 years, with the latest figure at $236.0 million for Q3 2025.

  • For Q3 2025, Assets Average fell 49.83% year-over-year to $236.0 million; the TTM value through Sep 2025 reached $236.0 million, down 49.83%, while the annual FY2024 figure was $429.0 million, 2.25% down from the prior year.
  • Assets Average for Q3 2025 was $236.0 million at Sutro Biopharma, down from $291.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $470.4 million in Q3 2024 and bottomed at $236.0 million in Q3 2025.
  • The 5-year median for Assets Average is $382.5 million (2023), against an average of $382.7 million.
  • The largest annual shift saw Assets Average skyrocketed 142.6% in 2021 before it tumbled 49.83% in 2025.
  • A 5-year view of Assets Average shows it stood at $356.4 million in 2021, then increased by 13.29% to $403.8 million in 2022, then rose by 11.74% to $451.2 million in 2023, then fell by 7.03% to $419.5 million in 2024, then crashed by 43.74% to $236.0 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Assets Average are $236.0 million (Q3 2025), $291.9 million (Q2 2025), and $354.3 million (Q1 2025).